Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Congress 2022

Antibody drug conjugates (ADCs) and breast cancer: Achievements and prospects

Why and how may antibody drug conjugates make rapid moves to earlier disease phases

Date

04 Dec 2022

Session

Antibody drug conjugates (ADCs) and breast cancer: Achievements and prospects

Topics

Translational Research

Tumour Site

Breast Cancer

Presenters

Sherene Loi

Authors

S. Loi

Author affiliations

  • Translational Breast Cancer Genomics Lab - Research, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Q&A and discussion

Presenter: Sherene Loi

Session: Antibody drug conjugates (ADCs) and breast cancer: Achievements and prospects

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.